Fonte: Blood Advances. Unidades: FMRP, FCFRP
Assuntos: TRANSPLANTES, CÉLULAS-TRONCO, SISTEMA IMUNE, LINFÓCITOS T, TRANSPLANTE AUTÓLOGO, TIMO (GLÂNDULA ENDÓCRINA)
ABNT
ARRUDA, Lucas C. M. et al. Immune rebound associates with a favorable clinical response to autologous HSCT in systemic sclerosis patients. Blood Advances, v. 2, n. 2, p. 126-141, 2018Tradução . . Disponível em: https://doi.org/10.1182/bloodadvances.2017011072. Acesso em: 02 nov. 2024.APA
Arruda, L. C. M., Farias, K. C. R. M. de, Lima Júnior, J. R., Clave, E., Dias, J. B. E., Moraes, D. A., et al. (2018). Immune rebound associates with a favorable clinical response to autologous HSCT in systemic sclerosis patients. Blood Advances, 2( 2), 126-141. doi:10.1182/bloodadvances.2017011072NLM
Arruda LCM, Farias KCRM de, Lima Júnior JR, Clave E, Dias JBE, Moraes DA, Douay C, Fournier I, Moins-Teisserenc H, Alberdi AJ, Covas DT, Simões BP, Lansiaux P, Oliveira MC. Immune rebound associates with a favorable clinical response to autologous HSCT in systemic sclerosis patients [Internet]. Blood Advances. 2018 ; 2( 2): 126-141.[citado 2024 nov. 02 ] Available from: https://doi.org/10.1182/bloodadvances.2017011072Vancouver
Arruda LCM, Farias KCRM de, Lima Júnior JR, Clave E, Dias JBE, Moraes DA, Douay C, Fournier I, Moins-Teisserenc H, Alberdi AJ, Covas DT, Simões BP, Lansiaux P, Oliveira MC. Immune rebound associates with a favorable clinical response to autologous HSCT in systemic sclerosis patients [Internet]. Blood Advances. 2018 ; 2( 2): 126-141.[citado 2024 nov. 02 ] Available from: https://doi.org/10.1182/bloodadvances.2017011072